MedTrace Logo

FGF-1 for Topical Administration for the Treatment of Diabetic or Venous Stasis Ulcers

NCT00425178 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2019-11-01

No results posted yet for this study

Summary

FGF-1 is being used for the treatment of patients with diabetic or venous stasis ulcers. Procedure includes topical administration of FGF-1 or placebo and evaluation of safety, pharmacokinetics, and wound improvement.

Conditions

  • Chronic Wounds
  • Diabetes
  • Venous Stasis Ulcers

Interventions

DRUG

FGF-1

Sponsors & Collaborators

  • Warren General Hospital

    collaborator UNKNOWN

  • CardioVascular BioTherapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Thomas E Serena, MD · Warren General Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-02
Primary Completion
2006-09-02
Completion
2006-12-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00425178 on ClinicalTrials.gov